Miranda-Filho A, Lortet-Tieulent J, Bray F et al (2021) Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol 9(4):225–234. https://doi.org/10.1016/S2213-8587(21)00027-9

Article  PubMed  Google Scholar 

Seib CD, Sosa JA (2019) Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am 48(1):23–35. https://doi.org/10.1016/j.ecl.2018.10.002

Article  PubMed  Google Scholar 

Filetti S, Durante C, Hartl D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 30(12):1856–1883. https://doi.org/10.1093/annonc/mdz400

Haddad RI, Bischoff L, Ball D et al (2022) Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(8):925–951. https://doi.org/10.6004/jnccn.2022.0040

Lee J, Lee SG, Kim K et al (2019) Clinical value of lymph node ratio integration with the 8(th) edition of the UICC TNM classification and 2015 ATA risk stratification systems for recurrence prediction in papillary thyroid cancer. Sci Rep 9(1):13361. https://doi.org/10.1038/s41598-019-50069-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rui ZY, Liu Y, Zheng W et al (2021) A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis. Clin Exp Med 21(2):277–286. https://doi.org/10.1007/s10238-020-00675-8

Article  PubMed  Google Scholar 

Wagner K, Abraham E, Tran B et al (2020) Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma. ANZ J Surg 90(9):1727–1732. https://doi.org/10.1111/ans.16202

Article  PubMed  Google Scholar 

Ulisse S, Baldini E, Lauro A et al (2021) Papillary thyroid cancer prognosis: an evolving field. Cancers (Basel) 13(21). https://doi.org/10.3390/cancers13215567

Waseem A, Dogan B, Tidman N et al (1999) Keratin 15 expression in stratified epithelia: downregulation in activated keratinocytes. J Invest Dermatol 112(3):362–369. https://doi.org/10.1046/j.1523-1747.1999.00535.x

Article  CAS  PubMed  Google Scholar 

Chen W, Miao C (2022) KRT15 promotes colorectal cancer cell migration and invasion through beta-catenin/MMP-7 signaling pathway. Med Oncol 39(5):68. https://doi.org/10.1007/s12032-021-01619-2

Article  CAS  PubMed  Google Scholar 

Giroux V, Stephan J, Chatterji P et al (2018) Mouse intestinal Krt15+ Crypt cells are radio-resistant and tumor initiating. Stem Cell Reports 10(6):1947–1958. https://doi.org/10.1016/j.stemcr.2018.04.022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tai G, Ranjzad P, Marriage F et al (2013) Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas. PLoS One 8(11):e81167. https://doi.org/10.1371/journal.pone.0081167

Yang H, Li A, Li A et al (2022) Upregulated keratin 15 links to the occurrence of lymphovascular invasion, stromal cervical invasion as well as unfavorable survival profile in endometrial cancer patients. Medicine (Baltimore) 101(29):e29686. https://doi.org/10.1097/MD.0000000000029686

Rao X, Wang J, Song HM et al (2020) KRT15 overexpression predicts poor prognosis in colorectal cancer. Neoplasma 67(2):410–414. https://doi.org/10.4149/neo_2019_190531N475

Article  CAS  PubMed  Google Scholar 

Zhong P, Shu R, Wu H et al (2021) Low KRT15 expression is associated with poor prognosis in patients with breast invasive carcinoma. Exp Ther Med 21(4):305. https://doi.org/10.3892/etm.2021.9736

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Chen P, Li Z et al (2023) Clinical implication of keratin-15 quantification for renal cell carcinoma management: its dysregulation and association with clinicopathologic characteristics and prognostication. Tohoku J Exp Med. https://doi.org/10.1620/tjem.2023.J017

Article  PubMed  Google Scholar 

Schmid KW, Synoracki S, Dralle H, Wittekind C (2019) Proposal for an extended pTNM classification of thyroid carcinoma : commentary on deficits of the 8th edition of the TNM classification. Pathologe 40(Suppl 1):18–24. https://doi.org/10.1007/s00292-018-0418-x

Peng W, Li W, Zhang X et al (2022) The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication. J Clin Lab Anal 36(9):e24609. https://doi.org/10.1002/jcla.24609

Makki FM, Taylor SM, Shahnavaz A et al (2013) Serum biomarkers of papillary thyroid cancer. J Otolaryngol Head Neck Surg 42(1):16. https://doi.org/10.1186/1916-0216-42-16

Article  PubMed  PubMed Central  Google Scholar 

Viana AOR, Goncalves Filho J, Francisco ALN et al (2020) Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma. Acta Otorhinolaryngol Ital 40(3):190–197. https://doi.org/10.14639/0392-100X-N0311

Abouhashem NS, Talaat SM (2017) Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathol Res Pract 213(5):509–517. https://doi.org/10.1016/j.prp.2017.01.017

Article  CAS  PubMed  Google Scholar 

Abbas O, Richards JE, Yaar R, Mahalingam M (2011) Stem cell markers (cytokeratin 15, cytokeratin 19 and p63) in in situ and invasive cutaneous epithelial lesions. Mod Pathol 24(1):90–97. https://doi.org/10.1038/modpathol.2010.180

Article  CAS  PubMed  Google Scholar 

Zhang C, Liang Y, Ma MH et al (2019) KRT15, INHBA, MATN3, and AGT are aberrantly methylated and differentially expressed in gastric cancer and associated with prognosis. Pathol Res Pract 215(5):893–899. https://doi.org/10.1016/j.prp.2019.01.034

Article  CAS  PubMed  Google Scholar 

Ciappuccini R, Heutte N, Lasne-Cardon A et al (2020) Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome. BMC Cancer 20(1):765. https://doi.org/10.1186/s12885-020-07269-3

Article  PubMed  PubMed Central  Google Scholar 

Coca-Pelaz A, Shah JP, Hernandez-Prera JC et al (2020) Papillary thyroid cancer-aggressive variants and impact on management: a narrative review. Adv Ther 37(7):3112–3128. https://doi.org/10.1007/s12325-020-01391-1

Article  PubMed  PubMed Central  Google Scholar 

Lin JB, Feng Z, Qiu ML et al (2020) KRT 15 as a prognostic biomarker is highly expressed in esophageal carcinoma. Future Oncol 16(25):1903–1909. https://doi.org/10.2217/fon-2019-0603

Article  CAS  PubMed  Google Scholar 

Khanom R, Sakamoto K, Pal SK et al (2012) Expression of basal cell keratin 15 and keratin 19 in oral squamous neoplasms represents diverse pathophysiologies. Histol Histopathol 27(7):949–959. https://doi.org/10.14670/HH-27.949

Evangelista MT, North JP (2015) Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma. J Cutan Pathol 42(11):824–831. https://doi.org/10.1111/cup.12546

Article  PubMed  Google Scholar 

Kim Y, Roh JL, Song DE et al (2020) Risk factors for posttreatment recurrence in patients with intermediate-risk papillary thyroid carcinoma. Am J Surg 220(3):642–647. https://doi.org/10.1016/j.amjsurg.2020.01.049

Article  PubMed  Google Scholar